Overview

A Study of the Safety of REN001 in Patients With Fatty Acid Oxidation Disorders

Status:
Recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess REN001 safety in subjects with fatty acid oxidation disorders.
Phase:
Phase 1
Details
Lead Sponsor:
Reneo Pharma Ltd